All Comments by John Trojanowski

  1. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.
  2. Anchorless prion protein results in infectious amyloid disease without clinical scrapie.
  3. The cell cycle in Alzheimer disease: a unique target for neuropharmacology.
  4. Counting costs. Patients will suffer from limits on Alzheimer's drugs.
  5. Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability.
  6. Do Alzheimer's disease patients want to participate in a treatment decision, and would their caregivers let them?
  7. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease.
  8. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe.
  9. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice.
  10. Visualizing Success with MRI of Amyloid Plaques in Live Mice
  11. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice.
  12. Not Just a Family Affair: Dardarin Mutations Predict Sporadic PD
  13. Caught in the Act—Amyloid Damages Neurons
  14. Lysosomes and Proteasomes Compete for PD Researchers' Attention
  15. Tackling Alzheimer’s from the Outside In